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Abstract: Efficient synthesis of NAD+ is critical to maintaining cell viability in all organs of the body. However, little is known of 
the pathway(s) by which cells of the central nervous system produce NAD+. The aim of this study was to investigate the relationship, 
between tryptophan degradation via the kynurenine pathway (KP) and de novo NAD+ synthesis in human astrocytes, a major cell type 
within the brain. In this study we observed that inhibition of single enzymes of the KP resulted in significant decreases in NAD+ levels in 
astroglial cells after a 24 hr period. We also observed that astrocytes cultured in media deficient in tryptophan, nicotinic acid and nicoti-
namide resulted in a 50% decrease in NAD+ levels after 24 hrs. This decrease in NAD+ was partially restored by supplementation of the 
culture media with either tryptophan or kynurenine, or nicotinic acid or with supply of the salvage pathway precursor nicotinamide.
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Introduction
Nicotinamide  adenine  dinucleotide  (NAD+),  as  the 
  parent molecule for the pyridine family of   nucleotides, 
(NADH,  NADP  and  NADPH)  is  an  important 
  coenzyme enabling electron transfer in the   oxidative 
production of ATP and for hydride ion transfer in 
many  enzyme  reactions.  Depleted  mitochondrial 
NAD+ impairs respiration and ATP   synthesis   resulting 
in energy crisis and cell death.1 More recently NAD+ 
has also been identified as a primary substrate for 
other  important  enzymes  including  poly  (ADP-
  ribose) polymerase (PARP) and the sirtuin family of 
de-acetylase enzymes. PARP is a nuclear enzyme, 
activated by DNA strand breaks that are involved in 
DNA repair and maintenance of genomic integrity. 
PARP uses up NAD+ to make ADP ribose polymers. 
An increase in DNA damage (often due to oxidative 
stress) can rapidly deplete the cell of NAD+ resulting 
in reduced ATP production and cell death.2,3 NAD+ is 
also a substrate for a relatively new class of NAD+ 
dependent de-acetylase enzymes called the sirtuins 
(SIRT1-7). Sirtuin enzymes consume NAD+ in the 
process of removal of acetyl groups from   histone 
and  non-histone    moieties.  Sirtuin  targets  consist 
of  a    variety  of    transcription  factors  and  proteins 
involved in important processes, such as stress resis-
tance and cell survival.4 Enhancing   sirtuin activity 
has been shown to promote   longevity in a range of 
  organisms.5 As NAD+ plays a central role in these 
cellular   systems, synthesis of NAD+ is essential to 
ensuring the health of the cell and associated organ 
systems.
De  novo  synthesis  of  NAD+  from  tryptophan 
through the kynurenine pathway (KP) has been   studied 
in the periphery and established as a primary source 
of NAD+, in the kidney and liver.6 We have previously 
reported that in the rat central nervous system (CNS), 
NAD+ concentrations can be regenerated in   astrocytes 
using nicotinic acid,   nicotinamide or quinolinic acid7 
and that some downstream KP metabolites can affect 
NAD+  levels  in  human    astrocytes.8  However  the 
relative  importance  of  KP  and/or    salvage  pathway 
(Fig. 1) metabolism to NAD+ synthesis in   primary 
human  brain  cells  is  yet  to  be    clarified.  We  have 
  earlier reported that human   astrocytes are deficient 
in one of the enzymes of the tryptophan to NAD+ 
metabolic cascade.9 It is therefore not clear whether 
  tryptophan catabolism is involved in NAD+ synthesis 
in these cells. Clarification of this question is impor-
tant as NAD+ depletion is   becoming increasingly rec-
ognised as a cause of cell death in CNS inflammatory 
and degenerative disorders.10
The aim of this study was therefore to   investigate 
the relationship, between kynurenine pathway (KP) 
metabolism and de novo NAD+ synthesis in   astrocytes, 
the  most  numerous  cell  type  of  the  CNS.  Results 
from  this  study,  showing  the  dependence  of  CNS 
cells on KP metabolism for NAD+   synthesis, implies 
that the KP could represent a significant   clinical and 
  therapeutic target.
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Figure 1. Schematic of NAD+ Biosynthesis; de novo and Salvage Pathways. (a) Indoleamine 2,3 dioxygenase 1 (1&2), (b) kynurenine formylase,   
(c) kynurenine 3-hydroxylase, (d) kynureninase, (e) 3-hydroxyanthranilic acid   oxidase, (f) quinolinic acid phosphoribosyl transferase, (g) nicotinic acid 
  phosphoribosyltransferase  (h)  nicotinic  acid  mononucleotide    adenylyltransferase  (i)    Glutamine  dependent  NAD+  synthetase,  (j)  Poly  (ADP  ribose) 
  polymerase (PARP), (k) nicotinamide phosphoribosyltransferase OR pre-B-cell   enhancing factor, (l) nicotinic acid mononucleotide adenylyltransferase. 
(α) This reaction proceeds non-enzymatically.
Abbreviations:  NIC,  nicotinic  acid;  NAMN,  nicotinic  acid  mononucleotide;  NAAD,  nicotinic  acid  adenine  dinucleotide;  NAD,  nicotinamide  adenine 
  dinucleotide; NAM, nicotinamide; NMN, nicotinamide mononucleotide.NAD synthesis from KP
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Materials and Methods
Reagents and chemicals
All cell culture media and supplements were   purchased 
from Invitrogen (Australia) unless   otherwise stated. 
All  reagents  and  chemicals  used  in  experiments 
were purchased from Sigma Aldrich Chemical Co. 
(  Australia) unless otherwise stated.
Cell cultures
Human primary astrocytes were grown in uncoated 
flasks  (Falcon)  and  maintained  in  complete  media 
(cRPMI), which contains RPMI 1640 media supple-
mented  with  10%  foetal  bovine  serum  (FBS),  1% 
2 mM glutamine (Sigma Aldrich, Australia) and 1% 
penicillin/streptomycin  (Sigma  Aldrich,    Australia). 
As part of its normal commercial formulation cRPMI 
  contains 24 µM tryptophan and 8 µM nicotinamide. 
The cell medium was changed twice a week, and all 
cell cultures were kept incubated at 37 °C in 5% CO2.9
A day prior to experimental treatments, cultures 
were  trypsinised  (Trypsin  0.25%)  and  seeded  at 
desired cell density, into 24 well plates (Falcon).
NAD+ precursor depleted RPMI
Depleted  RPMI  (dRPMI)  was  prepared  using  a 
  standard  mix  formula  for  RPMI  that  included  all 
nutrients except tryptophan (TRYP) and nicotinamide 
(NAM). Note that standard RPMI does not contain 
nicotinic acid (NIC) or kynurenine (KYN).
The dRPMI medium containing 10% FBS, 1% 
2 mM glutamine (Sigma Aldrich, Australia) and 1% 
penicillin/streptomycin  (Sigma  Aldrich,  Australia) 
was  supplemented  as  required  with  the  addition 
of substrates TRYP (25 µM), KYN (25 µM) NAM 
(10 µM) or NIC (10 µM). The concentrations chosen 
for  TRYP  and  NAM  supplementation  correspond 
to that found in the commercially prepared RPMI 
(cRPMI). As KYN is not present in RPMI media 
this upstream metabolite was added at a concentra-
tion   comparable to TRYP, which has been shown to 
increase in the culture medium of stimulated astro-
glial cells.13 NIC (the acid form of vitamin B3) is also 
not   normally present in RPMI media and was added 
at the same concentration as its amide form, NAM 
to allow direct comparison. All   supplements were 
prepared as sterile solutions in purified (.10 mΩ) 
water).
NAD+ precursor supplementation
Astrocytes were seeded into a 24-well culture plate at 
a density of 1 × 105 cells/ml in and left to   equilibrate 
in 5% CO2 at 37 °C in complete RPMI (cRPMI) for 
24 hr. The culture medium was then aspirated and 
each well was washed twice with warm phosphate 
buffered saline (PBS) before addition of 1 ml of fresh 
dRPMI (containing no TRYP, NAM or NIC). Selected 
NAD+  substrates  TRYP  (25  µM),  KYN  (25  µM) 
NAM (10 µM) or NIC (10 µM) were then added to 
  appropriate cultures for 24 hrs before analysis.
Kp enzyme inhibition
Human primary astrocytes were plated into 24-well 
plates at a density of 1 × 105 cells/ml in cRPMI and left 
to equilibrate for 24 hours before treatment.   Cultured 
medium was aspirated from each well, washed twice 
with warm phosphate buffered saline (PBS), before 
addition of 1 ml of fresh cRPMI followed by addition 
of specific inhibitors (Table 1) for 24 hrs.
NAD+ analysis
Cultured  medium  was  aspirated  from  each  well. 
The  cells  were  washed  twice  with  PBS,  before 
being homogenised by sonication in 500 µl of PBS 
(  containing 12 mM nicotinamide as a PARP   inhibitor). 
Quantification of NAD+ (H) in the cell was measured 
using the Thiazolyl blue microcycling assay11 adapted 
to a 96-well format.7
Total protein assay
Cultured  medium  was  removed  from  each  well 
and the cells were washed twice with PBS, before 
Table 1. Inhibitors used in the experiments.
Inhibitor concentration 
(mM)
Action/notes
1-methyl-Tryptophan 
(1-MT)δ
1  Competitive 
IDO inhibitor 
3-ethoxy-β-carboline 
(3-EBC)ψ
0.2  Non-
competitive 
IDO inhibitor 
Phthalic Acid 
(PHTH)χ
0.04  ‘Dead-end’ 
inhibitor of 
QPRT
notes: δPrevious  studies  have  shown  maximal  IDO1  inhibition  using 
1 mM 1-MT.15 ψWe have previously shown that 0.2 mM 3-EBC results in a 
maximal decrease in IDO1 activity in astroglial cells without measurable 
toxicity.13 χDose response analysis showed a maximal effect using PHTH 
at 0.04 mM (unpublished data).Grant et al
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being homogenised by sonication in 500 µl of PBS 
(  containing 12 mM nicotinamide as a PARP   inhibitor). 
The total protein per sample was measured using the 
commercially available Bradford assay method and 
reagents (BIORAD, Sydney, Australia), adapted to a 
96-well microtitre plate format, using a 595 nm filter 
in a Multiskan MS microplate reader.
Statistical analysis
For all culture samples, significant differences between 
treatment groups, at P , 0.05 level of   significance, 
were  determined  using  One-way  ANOVA  and 
  Dunnett’s multiple comparison test. All results are 
represented as mean ± standard error mean.
Results
Involvement of KP enzymes in de novo  
NAD+ synthesis
To determine whether tryptophan catabolism via the 
KP played a role in NAD+ synthesis, we used small 
molecule inhibitors that reduced the activity of   critical 
enzymes at the beginning and end of the KP.
Inhibition  of  the  initial  rate  limiting  enzyme 
indoleamine 2,3 dioxygenase (IDO1) with either the 
competitive inhibitor, 1-methyl tryptophan (1-MT) or 
the non-competitive inhibitor, 3-ethoxy-β-carboline 
(3EBC)  significantly  decreased  intracellular  NAD+ 
by 14% and 26% respectively after 24 hrs. In a simi-
lar fashion, inhibition of the downstream KP enzyme, 
quinolinic  acid  phosphoribosyl  transferase  (QPRT) 
with  the  dead-end  inhibitor  phthalic  acid  (PHTH) 
resulted in a significant 29% decrease in intracellular 
NAD+ levels after 24 hrs (Fig. 2).
Importance of de novo and salvage 
pathway precursors to NAD+ synthesis
To help verify that the results obtained for enzyme 
inhibition were specific to KP metabolism, we tested 
whether  the  removal  of  KP  or  salvage    pathway 
  precursors (i.e. tryptophan, nicotinic acid and nicotin-
amide) from the incubation medium affected cellular 
NAD+ levels.
We  found  that  in  the  absence  of  all  of  these 
  precursors a significant decrease of 50% in intracel-
lular NAD+ levels after 24 hrs was observed (Fig. 3).
Subsequent  supplementation  of  the  incubation 
medium with the upstream KP precursor tryptophan 
alone, increased NAD+ levels by 75% within 24 hrs 
compared  to  control. Addition  of  nicotinic  acid  to 
the  culture  medium  also  increased  NAD+  levels 
  significantly by 54% after 24 hrs (Fig. 3). Though 
an    apparent  increase  in  NAD+  was  observed  with 
kynurenine and nicotinamide supplementation, these 
did not reach statistical significance (Fig. 3).
discussion
We have previously shown that KP metabolism is 
linked to the maintenance of NAD+ levels in murine 
primary  astrocytes  and  human  and  murine  cell 
lines.7,12,13 However, following the observation that 
primary  human  astrocytes  do  not  express  the  KP 
enzyme, kynurenine 3-hydroxylase,9 we were unsure 
whether these cells could efficiently use tryptophan 
for  NAD+  synthesis.  Using  the  dual  approach  of 
enzyme inhibition and NAD+ substrate depletion, we 
investigated the role of the KP and salvage pathway 
metabolism in the maintenance of NAD+ concentra-
tions in primary human astrocytes.
In the present study, we observed that intracellular 
NAD+ levels decreased significantly following inhi-
bition of either the initial or downstream KP enzymes 
IDO1 or QPRT, respectively (Fig. 2). These results 
are consistent with our previous findings showing a 
clear relationship between IDO activity and NAD+ 
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Figure 2. Effect of inhibition of selected KP enzymes on NAD+ levels 
in  primary  human  astrocytes.  Cellular  NAD+  levels  were  significantly 
reduced in primary human   astrocyte cultures (1  105 cells/ml) following 
treatment with: The   competitive IDO inhibitor 1-methyl tryptophan (1-MT, 
1 mM) or the   non-competitive IDO inhibitor, 3-ethoxy, β carboline (3-EBC, 
0.2 mM) or the QPRT inhibitor phthalic acid (PHTH, 0.04 mM) for 24 hrs. 
note: *P , 0.05 compared to control, (n = 4 for each treatment group).NAD synthesis from KP
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levels in a human astroglioma cell line.13   Supporting 
these  results,  we  also  observed  that  intracellular 
NAD+   levels decreased significantly after 24 hrs in the 
absence of either KP metabolites or salvage   pathway 
substrates in the incubation medium (Fig. 3).
The subsequent regeneration of NAD+ from TRYP, 
KYN, NIC or NAM (Fig. 3) strongly suggests the 
metabolic use of these precursors in the production 
of NAD+.
This result is similar to our previous reports showing 
that quinolinic acid or nicotinic acid or nicotinamide 
were able to regenerate NAD+ after oxidative stress in 
murine primary astrocytes7. In the present study the 
observation that primary human astrocytes regenerated 
NAD+ more efficiently from NIC than NAM when sup-
plied in equimolar concentrations (Fig. 3) is indicative 
of preferred metabolism from this source. This is again 
consistent with our previous report in murine primary 
astrocytes showing NIC was also more efficient at pro-
moting NAD+ regeneration than the amide.7
Taken together these results support the hypothesis 
that the KP is an important route for NAD+ synthesis 
in primary human astroglial cells. As this occurs in 
Figure 3. Effect of substrate availability on cellular NAD+ levels in   primary 
human  astrocytes.  Primary  human  astrocytes  grown  in  either  dRPMI 
(RPMI with 10% FBS without the NAD+ precursors tryptophan,   nicotinic 
acid or nicotinamide) or cRPMI (complete RPMI with 10% FBS   containing 
tryptophan and nicotinamide) ± addition of the specific NAD+ precursors 
tryptophan (TRYP, 25 µM), nicotinic acid, (NIC, 10 µM),   nicotinamide 
(NAM,  10  µM)  or  kynurenine  (KYN,  25  µM)  for  24  hrs  resulted  in  a 
  significant increase in NAD+ levels. 
note: *P , 0.05 compared to control (n = 3–4 for each treatment group).
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spite of the previously reported absence of kynurenine 
3-hydroxylase,9 the progress around this blockade to 
NAD+ most likely occurs via efficient non-enzymatic 
hydroxylation  of  anthranilic  acid  to  3-hydroxyan-
thranilic acid (Fig. 1). This is consistent with studies 
done some time ago by Henderson et al who reported 
that kynurenine could be converted to niacin (NAD+) 
in  kidney  and  liver  tissue  through    non-enzymatic 
hydroxylation.16
Importantly, though tryptophan catabolism via the 
KP clearly results in NAD+ production, significant 
synthetic capacity is also possible via nicotinic acid 
or nicotinamide and the salvage pathway (Fig. 3).
With  growing  interest  in  IDO1  inhibition  as  a 
  therapeutic target14 coupled with the fact that   maintaining 
NAD+ levels is an essential part of organ health10 char-
acterisation of NAD+ metabolism in other cells of the 
CNS such as neurons and microglia are needed.   Further 
research  is  also  required  to  confirm  whether  NAD+ 
  levels  can  be  effectively  maintained  when  IDO1  or 
other KP enzymes are inhibited by   concurrent addition 
of NIC or salvage pathway precursors such NAM.
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